Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 11457-11467

  Wang, Zekun ^a   Ni, Jinjing ^a   Li, Jianhua ^a   Shi, Bisheng ^a   Xu, Yang ^a   Yuan, Zhenghong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; DNA POLYMERASE; INHIBITOR OF APOPTOSIS PROTEIN 2; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEGRADATION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; UBIQUITINATION; VIRUS INHIBITION; VIRUS REPLICATION;

CELL LINE; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION MAPPING; RNA, VIRAL; UBIQUITIN; VIRAL PROTEINS; VIRUS ASSEMBLY; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 80055102051     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00879-11     Document Type: Article

References (49)

1. Ardley, H. C., and P. A. Robinson. 2005. E3 ubiquitin ligases. Essays Biochem. 41:15-30.
2. Bartenschlager, R., M. Junker-Niepmann, and H. Schaller. 1990. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J. Virol. 64:5324-5332.
3. Bertrand, M. J., et al. 2009. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30:789-801.
4. Biermer, M., R. Puro, and R. J. Schneider. 2003. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-kB. J. Virol. 77:4033-4042.
5. Bird, P. I., J. A. Trapani, and J. A. Villadangos. 2009. Endolysosomal proteases and their inhibitors in immunity. Nat. Rev. Immunol. 9:871-882.
6. Bouchard, M. J., L. H. Wang, and R. J. Schneider. 2001. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 294:2376-2378.
7. Cao, F., and J. E. Tavis. 2004. Detection and characterization of cytoplasmic hepatitis B virus reverse transcriptase. J. Gen. Virol. 85:3353-3360.
8. de Bettignies, G., and O. Coux. 2010. Proteasome inhibitors: dozens of molecules and still counting. Biochimie 92:1530-1545.
9. de Franchis, R., et al. 2003. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002, Geneva, Switzerland. Consensus statement (long version). J. Hepatol 39(Suppl. 1):S3-S25.
10. Fallows, D. A., and S. P. Goff. 1995. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J. Virol. 69:3067-3073.
11. Fouillot, N., S. Tlouzeau, J. M. Rossignol, and O. Jean-Jean. 1993. Translation of the hepatitis B virus P gene by ribosomal scanning as an alternative to internal initiation. J. Virol. 67:4886-4895.
12. Gao, W., and J. Hu. 2007. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J. Virol. 81:6164-6174.
13. Glickman, M. H., and A. Ciechanover. 2002. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82:373-428.
14. Guidotti, L. G., and F. V. Chisari. 2001. Noncytolytic control of viral infec-tions by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65-91.
15. Guidotti, L. G., et al. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36.
16. Guidotti, L. G., et al. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829.
17. Harding, H. P., Y. Zhang, and D. Ron. 1999. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397:271-274.
18. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425-479.
19. Hu, J., and C. Seeger. 1996. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 93:1060-1064.
20. Hu, S., et al. 2006. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J. Clin. Invest. 116:174-181.
21. Hu, Z., et al. 1999. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J. Virol. 73:7231-7240.
22. Huang, H., et al. 2000. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J. Biol. Chem. 275:26661-26664.
23. Kim, J. H., S. Y. Sohn, T. S. Benedict Yen, and B. Y. Ahn. 2008. Ubiquitindependent and -independent proteasomal degradation of hepatitis B virus X protein. Biochem. Biophys. Res. Commun. 366:1036-1042.
24. Ko, A., et al. 2010. MKRN1 induces degradation of West Nile virus capsid protein by functioning as an E3 ligase. J. Virol. 84:426-436.
25. Ladner, S. K., et al. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
26. Li, J., et al. 2010. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J. Virol. 84:6387-6399.
27. Ling, M. T., et al. 2008. Id-1 induces proteasome-dependent degradation of the HBX protein. J. Mol. Biol. 382:34-43.
28. Liu, X., et al. 2005. Cellular cIAP2 gene expression associated with anti-HBV activity of TNF-α in hepatoblastoma cells. J. Interferon Cytokine Res. 25: 617-626.
29. Mahoney, D. J., et al. 2008. Both cIAP1 and cIAP2 regulate TNFα-mediated NF-kB activation. Proc. Natl. Acad. Sci. U. S. A. 105:11778-11783.
30. Mao, A. P., et al. 2010. Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-β) and cellular antiviral response. J. Biol. Chem. 285:9470-9476.
31. Puro, R., and R. J. Schneider. 2007. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J. Virol. 81:7351-7362.
32. Robek, M. D., B. S. Boyd, S. F. Wieland, and F. V. Chisari. 2004. Signal transduction pathways that inhibit hepatitis B virus replication. Proc. Natl. Acad. Sci. U. S. A. 101:1743-1747.
33. Robek, M. D., S. F. Wieland, and F. V. Chisari. 2002. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J. Virol. 76: 3570-3574.
34. Rothe, M., M. G. Pan, W. J. Henzel, T. M. Ayres, and D. V. Goeddel. 1995. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243-1252.
35. Sakamoto, E., et al. 2005. Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2. J. Leukoc. Biol. 78:301-309.
36. Salvesen, G. S., and C. S. Duckett. 2002. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3:401-410.
37. Seeger, C., and W. S. Mason. 2000. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64:51-68.
38. Sheikh, M. S., and A. J. Fornace, Jr. 1999. Regulation of translation initiation following stress. Oncogene 18:6121-6128.
39. Shirakura, M., et al. 2007. E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J. Virol. 81:1174-1185.
40. Tiollais, P., C. Pourcel, and A. Dejean. 1985. The hepatitis B virus. Nature 317:489-495.
41. Wegele, H., L. Muller, and J. Buchner. 2004. Hsp70 and Hsp90-a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 151:1-44.
42. Wieland, S. F., A. Eustaquio, C. Whitten-Bauer, B. Boyd, and F. V. Chisari. 2005. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc. Natl. Acad. Sci. U. S. A. 102: 9913-9917.
43. Xu, C., et al. 2010. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J. Virol. 84:9332-9340.
44. Yang, Y., et al. 2007. Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP). J. Cell. Biochem. 101:167-180.
45. Yu, S., et al. 2010. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKε and DDX3. J. Gen. Virol. 91:2080-2090.
46. Zarnegar, B. J., et al. 2008. Noncanonical NF-kB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9:1371-1378.
47. Zhang, Z., U. Protzer, Z. Hu, J. Jacob, and T. J. Liang. 2004. Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBXdependent manner. J. Virol. 78:4566-4572.
48. Zhang, Z., E. Sun, J. H. Ou, and T. J. Liang. 2010. Inhibition of cellular proteasome activities mediates HBX-independent hepatitis B virus replication in vivo. J. Virol. 84:9326-9331.
49. Zhang, Z., et al. 2000. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex. J. Biol. Chem. 275:15157-15165.